Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931191 | 0.94 | NR1H2 (0.45) | NR1H2ESR2UCHL1ADORA1GPR119 | |
| SCHEMBL8258476 | 0.82 | ESR2 (0.51) | NR1H2ESR2UCHL1ADORA1GPR119 | |
| SCHEMBL4176434 | 0.81 | NR1H2 (0.53) | NR1H2ESR2ADORA1GPR119DDB1 | |
| SCHEMBL8243756 | 0.81 | NR1H2 (0.41) | NR1H2ESR2UCHL1GPR119DDB1 | |
| SCHEMBL4165540 | 0.80 | NR1H2 (0.60) | NR1H2ESR2UCHL1ADORA1DDB1 | |
| SCHEMBL31067476 | 0.80 | NR1H2 (0.60) | NR1H2ESR2UCHL1ADORA1DDB1 | |
| SCHEMBL4172281 | 0.79 | ESR2 (0.58) | NR1H2ESR2GPR119DDB1CRBN | |
| SCHEMBL4171451 | 0.79 | NR1H2 (0.64) | NR1H2ESR2GPR119DDB1CRBN | |
| SCHEMBL4171919 | 0.79 | ESR2 (0.58) | NR1H2ESR2GPR119DDB1CRBN | |
| SCHEMBL4178857 | 0.78 | NR1H2 (0.54) | NR1H2ESR2ADORA1GPR119DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | NR1H2 3160/4885ESR2 3298/4885UCHL1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.